Does the media prefer GLUE or XENE?

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 4 mentions for Monte Rosa Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Monte Rosa Therapeutics' score of 0.24 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Xenon Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PBLS or GLUE?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Monte Rosa Therapeutics' score of 0.24 indicating that Parabilis Medicines is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Parabilis Medicines 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to GLUE or ACAD?

In the previous week, ACADIA Pharmaceuticals had 14 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 18 mentions for ACADIA Pharmaceuticals and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.24 beat ACADIA Pharmaceuticals' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ACADIA Pharmaceuticals 0 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 5 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer CELC or GLUE?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Celcuity. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Celcuity. Celcuity's average media sentiment score of 0.82 beat Monte Rosa Therapeutics' score of 0.24 indicating that Celcuity is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Celcuity 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Monte Rosa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor GLUE or CDNA?

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for CareDx. CareDx's average media sentiment score of 1.36 beat Monte Rosa Therapeutics' score of 0.24 indicating that CareDx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CareDx 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Monte Rosa Therapeutics (GLUE) Competitors

$9.89 -0.63 (-5.99%)

Closing price 10/13/2026 04:00 PM Eastern

Extended Trading

$9.95 +0.06 (+0.61%)

As of 08:47 AM Eastern

Compare

GLUE vs. XENE, PBLS, ACAD, CELC, and CDNA

Should you buy Monte Rosa Therapeutics stock or one of its competitors? Monte Rosa Therapeutics's main competitors and comparable companies include Xenon Pharmaceuticals (XENE), Parabilis Medicines (PBLS), ACADIA Pharmaceuticals (ACAD), Celcuity (CELC), and CareDx (CDNA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Monte Rosa Therapeutics compare to Xenon Pharmaceuticals?

Monte Rosa Therapeutics (NASDAQ:GLUE) and Xenon Pharmaceuticals (NASDAQ:XENE) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

In the previous week, Xenon Pharmaceuticals had 4 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 8 mentions for Xenon Pharmaceuticals and 4 mentions for Monte Rosa Therapeutics. Xenon Pharmaceuticals' average media sentiment score of 0.61 beat Monte Rosa Therapeutics' score of 0.24 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Xenon Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Monte Rosa Therapeutics currently has a consensus price target of $26.67, suggesting a potential upside of 169.63%. Xenon Pharmaceuticals has a consensus price target of $70.14, suggesting a potential upside of 103.79%. Given Monte Rosa Therapeutics' higher possible upside, equities research analysts plainly believe Monte Rosa Therapeutics is more favorable than Xenon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
Xenon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.87

Monte Rosa Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, Xenon Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the broader market.

Monte Rosa Therapeutics has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	6.82	-$38.63M	-$1.76	N/A
Xenon Pharmaceuticals	$7.50M	443.65	-$345.91M	-$4.74	N/A

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 2.9% of Xenon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Xenon Pharmaceuticals has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Xenon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
Xenon Pharmaceuticals	N/A	-43.98%	-41.72%

Summary

Monte Rosa Therapeutics beats Xenon Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Parabilis Medicines (NASDAQ:PBLS) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends, risk and media sentiment.

Parabilis Medicines has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Parabilis Medicines' return on equity of 0.00% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Parabilis Medicines	N/A	N/A	N/A
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Parabilis Medicines. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Parabilis Medicines. Parabilis Medicines' average media sentiment score of 0.98 beat Monte Rosa Therapeutics' score of 0.24 indicating that Parabilis Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Parabilis Medicines	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Monte Rosa Therapeutics has higher revenue and earnings than Parabilis Medicines. Parabilis Medicines is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Parabilis Medicines	N/A	N/A	-$145.89M	-$2.13	N/A
Monte Rosa Therapeutics	$123.67M	6.82	-$38.63M	-$1.76	N/A

Parabilis Medicines currently has a consensus price target of $41.67, indicating a potential upside of 55.18%. Monte Rosa Therapeutics has a consensus price target of $26.67, indicating a potential upside of 169.63%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than Parabilis Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Parabilis Medicines	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.71
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Summary

Monte Rosa Therapeutics beats Parabilis Medicines on 9 of the 13 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to ACADIA Pharmaceuticals?

Monte Rosa Therapeutics (NASDAQ:GLUE) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, valuation, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

In the previous week, ACADIA Pharmaceuticals had 14 more articles in the media than Monte Rosa Therapeutics. MarketBeat recorded 18 mentions for ACADIA Pharmaceuticals and 4 mentions for Monte Rosa Therapeutics. Monte Rosa Therapeutics' average media sentiment score of 0.24 beat ACADIA Pharmaceuticals' score of 0.00 indicating that Monte Rosa Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ACADIA Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	8 Neutral mention(s)	5 Negative mention(s)	1 Very Negative mention(s)	Neutral

ACADIA Pharmaceuticals has a net margin of 33.42% compared to Monte Rosa Therapeutics' net margin of -560.85%. ACADIA Pharmaceuticals' return on equity of 9.03% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
ACADIA Pharmaceuticals	33.42%	9.03%	6.79%

Monte Rosa Therapeutics presently has a consensus price target of $26.67, suggesting a potential upside of 169.63%. ACADIA Pharmaceuticals has a consensus price target of $31.34, suggesting a potential upside of 68.32%. Given Monte Rosa Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
ACADIA Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.72

Monte Rosa Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.88, suggesting that its stock price is 12% less volatile than the broader market.

ACADIA Pharmaceuticals has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	6.82	-$38.63M	-$1.76	N/A
ACADIA Pharmaceuticals	$1.07B	2.99	$391M	$2.22	8.39

Summary

ACADIA Pharmaceuticals beats Monte Rosa Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to Celcuity?

Celcuity (NASDAQ:CELC) and Monte Rosa Therapeutics (NASDAQ:GLUE) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends, valuation and media sentiment.

Celcuity presently has a consensus target price of $154.25, suggesting a potential upside of 144.11%. Monte Rosa Therapeutics has a consensus target price of $26.67, suggesting a potential upside of 169.63%. Given Monte Rosa Therapeutics' higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than Celcuity.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 80.0% of Monte Rosa Therapeutics shares are owned by institutional investors. 13.3% of Celcuity shares are owned by company insiders. Comparatively, 6.4% of Monte Rosa Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Celcuity. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for Celcuity. Celcuity's average media sentiment score of 0.82 beat Monte Rosa Therapeutics' score of 0.24 indicating that Celcuity is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Celcuity	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Celcuity has a net margin of 0.00% compared to Monte Rosa Therapeutics' net margin of -560.85%. Monte Rosa Therapeutics' return on equity of -43.31% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-350.78%	-41.54%
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%

Celcuity has a beta of 0.1, suggesting that its stock price is 90% less volatile than the broader market. Comparatively, Monte Rosa Therapeutics has a beta of 1.37, suggesting that its stock price is 37% more volatile than the broader market.

Monte Rosa Therapeutics has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$4.30	N/A
Monte Rosa Therapeutics	$123.67M	6.82	-$38.63M	-$1.76	N/A

Summary

Monte Rosa Therapeutics beats Celcuity on 10 of the 14 factors compared between the two stocks.

How does Monte Rosa Therapeutics compare to CareDx?

Monte Rosa Therapeutics (NASDAQ:GLUE) and CareDx (NASDAQ:CDNA) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and earnings.

In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than CareDx. MarketBeat recorded 4 mentions for Monte Rosa Therapeutics and 3 mentions for CareDx. CareDx's average media sentiment score of 1.36 beat Monte Rosa Therapeutics' score of 0.24 indicating that CareDx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Monte Rosa Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CareDx	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Monte Rosa Therapeutics has a beta of 1.37, indicating that its share price is 37% more volatile than the broader market. Comparatively, CareDx has a beta of 2.38, indicating that its share price is 138% more volatile than the broader market.

Monte Rosa Therapeutics currently has a consensus target price of $26.67, indicating a potential upside of 169.63%. CareDx has a consensus target price of $54.00, indicating a potential downside of 17.47%. Given Monte Rosa Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Monte Rosa Therapeutics is more favorable than CareDx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
CareDx	0 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.38

CareDx has a net margin of 24.23% compared to Monte Rosa Therapeutics' net margin of -560.85%. CareDx's return on equity of 2.87% beat Monte Rosa Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-560.85%	-43.31%	-27.59%
CareDx	24.23%	2.87%	2.17%

CareDx has higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Monte Rosa Therapeutics	$123.67M	6.82	-$38.63M	-$1.76	N/A
CareDx	$379.80M	8.91	-$21.35M	$2.07	31.61

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 2.4% of CareDx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

CareDx beats Monte Rosa Therapeutics on 10 of the 17 factors compared between the two stocks.

Get Monte Rosa Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GLUE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GLUE vs. The Competition

Export

Metric	Monte Rosa Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$897.50M	$3.93B	$7.26B	$13.21B
Dividend Yield	N/A	3.65%	2.52%	22.89%
P/E Ratio	-5.62	11.07	204.95	19.81
Price / Sales	6.82	1,148.53	562.00	81.34
Price / Cash	N/A	118.50	77.16	53.04
Price / Book	2.76	17.07	10.75	6.03
Net Income	-$38.63M	-$22.69M	$3.50B	$380.34M
7 Day Performance	-2.75%	-4.42%	-2.90%	-2.34%
1 Month Performance	-28.85%	-12.47%	-7.37%	-5.31%
1 Year Performance	-6.79%	7.61%	2.97%	-2.94%

Monte Rosa Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GLUE Monte Rosa Therapeutics	2.3205 of 5 stars	$9.89 -6.0%	$26.67 +169.6%	-4.9%	$897.50M	$123.67M	N/A	173	Analyst Upgrade
XENE Xenon Pharmaceuticals	4.4056 of 5 stars	$36.59 +1.2%	$70.14 +91.7%	-13.9%	$3.54B	N/A	N/A	364	Analyst Downgrade
PBLS Parabilis Medicines	2.3968 of 5 stars	$28.65 +2.0%	$41.67 +45.4%	N/A	$3.54B	N/A	N/A	145
ACAD ACADIA Pharmaceuticals	4.6437 of 5 stars	$19.82 +1.2%	$32.71 +65.0%	-7.2%	$3.42B	$1.14B	8.94	798	Trending News Analyst Upgrade
CELC Celcuity	3.0005 of 5 stars	$67.85 0.0%	$154.25 +127.3%	+33.3%	$3.32B	N/A	N/A	155

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GLUE) was last updated on 10/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. XENE, PBLS, ACAD, CELC, and CDNA

How does Monte Rosa Therapeutics compare to Xenon Pharmaceuticals?

Summary

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Summary

How does Monte Rosa Therapeutics compare to ACADIA Pharmaceuticals?

Summary

How does Monte Rosa Therapeutics compare to Celcuity?

Summary

How does Monte Rosa Therapeutics compare to CareDx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Monte Rosa Therapeutics (GLUE) Competitors

GLUE vs. XENE, PBLS, ACAD, CELC, and CDNA

How does Monte Rosa Therapeutics compare to Xenon Pharmaceuticals?

Does the media prefer GLUE or XENE?

Do analysts recommend GLUE or XENE?

Which has more risk & volatility, GLUE or XENE?

Which has preferable valuation and earnings, GLUE or XENE?

Do institutionals and insiders have more ownership in GLUE or XENE?

Is GLUE or XENE more profitable?

Summary

How does Monte Rosa Therapeutics compare to Parabilis Medicines?

Is PBLS or GLUE more profitable?

Do institutionals & insiders believe in PBLS or GLUE?

Does the media favor PBLS or GLUE?

Which has higher valuation & earnings, PBLS or GLUE?

Do analysts prefer PBLS or GLUE?

Summary

How does Monte Rosa Therapeutics compare to ACADIA Pharmaceuticals?

Do insiders & institutionals have more ownership in GLUE or ACAD?

Does the media refer more to GLUE or ACAD?

Is GLUE or ACAD more profitable?

Do analysts recommend GLUE or ACAD?

Which has more risk & volatility, GLUE or ACAD?

Which has higher earnings & valuation, GLUE or ACAD?

Summary

How does Monte Rosa Therapeutics compare to Celcuity?

Do analysts rate CELC or GLUE?

Do insiders & institutionals hold more shares of CELC or GLUE?

Does the media prefer CELC or GLUE?

Is CELC or GLUE more profitable?

Which has more volatility & risk, CELC or GLUE?

Which has stronger earnings & valuation, CELC or GLUE?

Summary

How does Monte Rosa Therapeutics compare to CareDx?

Does the media favor GLUE or CDNA?

Which has more volatility and risk, GLUE or CDNA?

Do analysts rate GLUE or CDNA?

Is GLUE or CDNA more profitable?

Which has higher earnings and valuation, GLUE or CDNA?

Do institutionals and insiders believe in GLUE or CDNA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLUE vs. The Competition

Monte Rosa Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools